University College Hospital - London
Welcome,         Profile    Billing    Logout  
 29 Trials 
77 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ardeshna, Kirit
CRUK-2004-001621-16, NCT00112931 / 2004-001621-16: Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma

Checkmark P3 data
Jun 2011 - Jun 2011: P3 data
Checkmark P3 data
Dec 2010 - Dec 2010: P3 data
Completed
3
462
Europe, RoW
rituximab, No treatment
University College, London, Cancer Research UK, Roche Pharma AG
Lymphoma
03/14
09/23
Emberton, Mark
IP6-CHAIROS, NCT05228197: Imperial Prostate 6 - Cancer Histology Artificial Intelligence Reliability Study.

Recruiting
N/A
750
Europe
Biopsy & Imaging
Imperial College London, National Institute for Health Research, United Kingdom
Prostatic Neoplasms
07/24
12/24
PRIME, NCT04571840: Prostate Imaging Using MRI +/- Contrast Enhancement

Active, not recruiting
N/A
500
Europe, Canada, US, RoW
Multiparametric MRI +/- prostate biopsy, Biparametric MRI +/- prostate biopsy
University College, London
Prostate Cancer
12/24
03/25
NCT01194648: Focal Therapy for Prostate Cancer Using HIFU

Recruiting
N/A
354
Europe
questionnaire administration, assessment of therapy complications, high-intensity focused ultrasound ablation, multiparametric magnetic resonance imaging, quality-of-life assessment, transperineal prostate biopsy, transrectal prostate biopsy
University College, London
Male Erectile Disorder, Prostate Cancer, Therapy-related Toxicity, Urinary Incontinence
12/28
06/29
Ferrari, Andrea
CAMPFIRE, NCT05999994: A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

Recruiting
2
105
Europe, Japan, US, RoW
Ramucirumab, LY3009806, Cyclophosphamide, Vinorelbine, Gemcitabine, LY188011, Docetaxel, Abemaciclib, LY2835219, Irinotecan, Temozolomide
Eli Lilly and Company
Neoplasms, Child, Adolescent
05/27
05/27
NCT06229535: The Right to be Forgotten in the AYA Population: Patients' Experience and Perspectives (Diritto All'Oblio)

Recruiting
N/A
60
Europe
Centro di Riferimento Oncologico - Aviano
Oncologic Disorders
11/24
11/24
Roylance, Rebecca
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Calendar Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer
Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
PARTNER, NCT03150576: Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer

Recruiting
2/3
780
Europe
Olaparib, Lynparza, Paclitaxel and Carboplatin, Taxol and Paraplatin
Cambridge University Hospitals NHS Foundation Trust, AstraZeneca, Cancer Research UK
Breast Cancer
06/24
06/34
ROLo, NCT03620643 / 2017-001680-20: Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours

Active, not recruiting
2
58
Europe
Crizotinib Oral Capsule [Xalkori], Xalkori, Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex or generic], Faslodex
Royal Marsden NHS Foundation Trust, Pfizer, Breast Cancer Now
Lobular Breast Carcinoma, Gastric Cancer, Triple Negative Breast Cancer, CDH1 Gene Mutation
07/24
07/24
FAIM, NCT04920708: Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression

Recruiting
2
324
Europe
Ipatasertib 300mg, RG7440, Fulvestrant 500g, Faslodex, Palbociclib 75mg-125mg, Ibrance, CDK4/6 Inhibitor, Abemaciclib / Ribociclib / Palbociclib
Royal Marsden NHS Foundation Trust, Pfizer, Hoffmann-La Roche
Metastatic Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer
09/26
09/26
TRAK-ER, NCT04985266 / 2020-004022-36: A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer

Recruiting
2
1100
Europe
Palbociclib 125Mg Tab, Fulvestrant injection, Tamoxifen, Letrozole, Exemestane, Anastrozole
Royal Marsden NHS Foundation Trust, Pfizer, AstraZeneca, Institute of Cancer Research, United Kingdom, UNICANCER, Gustave Roussy, Cancer Campus, Grand Paris, Invitae Corporation
ER+ Breast Cancer, HER2-negative Breast Cancer
09/27
09/30
ELEVATE, NCT05563220: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer

Recruiting
1/2
400
Europe, US, RoW
Elacestrant, Alpelisib, Piqray, Everolimus, Afinitor, Ribociclib, Kisqali, Palbociclib, Ibrance, Capivasertib, Truqap, Abemaciclib, Verzenio
Stemline Therapeutics, Inc.
Breast Cancer, Metastatic Breast Cancer
12/24
08/26
PAveMenT, NCT04360941: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer

Recruiting
1
45
Europe
Palbociclib, Ibrance, Avelumab, Bavencio
Royal Marsden NHS Foundation Trust, Pfizer, Breast Cancer Now
Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Recurrent Breast Cancer, Metastatic Breast Cancer, ER+ Breast Cancer, HER2-positive Breast Cancer
07/25
12/25
Lee, Ming Ta Michael
LIBRETTO-432, NCT04819100 / 2020-005191-35: A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

Recruiting
3
170
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Placebo
Loxo Oncology, Inc., Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung
05/27
08/32
NCT05767788: Mobilization With Movement (MWM) on Knee Osteoarthritis (OA)

Active, not recruiting
N/A
40
RoW
Movement with Mobilization (MWM), Sham Movement with Mobilization (Sham MWM)
The Hong Kong Polytechnic University
Knee Osteoarthritis
05/23
05/23
Hernandez, Edgar
OnPrime, NCT05281471: Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (, GOG-3076)

Recruiting
3
186
US
olvimulogene nanivacirepvec, GL-ONC1 and GLV-1h68, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin, Bevacizumab (or biosimilar)
Genelux Corporation, GOG Foundation
Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High-grade Serous Ovarian Cancer, Endometrioid Ovarian Cancer, Ovarian Clear Cell Carcinoma
08/25
10/26
NCT04088396 / 2017-004495-60: A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)

Recruiting
3
58
Europe, Japan, RoW
Baricitinib, LY3009104, Tocilizumab
Eli Lilly and Company
Systemic Juvenile Idiopathic Arthritis
04/26
05/26
JUVE-X, NCT03773965 / 2017-004471-31: A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

Recruiting
3
190
Europe, Japan, RoW
Baricitinib, LY3009104
Eli Lilly and Company
Juvenile Idiopathic Arthritis
07/31
07/31
Ziegler, David
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study)

Calendar Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Calendar Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Recruiting
3
450
Europe, Canada, Japan, US, RoW
Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo
Chimerix
H3 K27M, Glioma
08/26
08/26
NCT06161974: Study of Olutasidenib and Temozolomide in HGG

Not yet recruiting
2
60
Europe, Canada, US, RoW
Olutasidenib + TMZ
Rigel Pharmaceuticals, Nationwide Children's Hospital
High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV, Diffuse Intrinsic Pontine Glioma, WHO Grade III Glioma, WHO Grade IV Glioma, Metastatic Brain Tumor, Diffuse Midline Glioma, H3 K27M-Mutant, Thalamus Tumor, Spinal Tumor, IDH1 Mutation, IDH1 R132, IDH1 R132C, IDH1 R132H, IDH1 R132S, IDH1 R132G, IDH1 R132L, Oligodendroglioma
06/29
06/35
NCT05233397: ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

Recruiting
2
38
Canada, US, RoW
Tocilizumab, ACTEMRA®
Nationwide Children's Hospital, Children's Hospital Colorado
Adamantinomatous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma
12/25
12/27
NCT05286788: MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

Recruiting
2
38
Canada, US, RoW
Binimetinib Oral Tablet [Mektovi], MEKTOVI
Nationwide Children's Hospital, Children's Hospital Colorado
Adamantinous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma
04/25
04/27
NCT05843253: Study of Ribociclib and Everolimus in HGG and DIPG

Recruiting
2
100
Europe, Canada, US, RoW
Ribociclib, Kisqali, Everolimus, Afinitor
Nationwide Children's Hospital, Novartis
High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma, Glioblastoma Multiforme, Diffuse Midline Glioma, H3 K27M-Mutant, Metastatic Brain Tumor, WHO Grade III Glioma, WHO Grade IV Glioma
08/28
08/34
NCT05839379: Targeted Pediatric High-Grade Glioma Therapy

Recruiting
2
450
Europe, Canada, US, RoW
Nationwide Children's Hospital
High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma, Glioblastoma Multiforme, Diffuse Midline Glioma, H3 K27M-Mutant, Metastatic Brain Tumor, WHO Grade III Glioma, WHO Grade IV Glioma
08/29
08/34
INFORM2 NivEnt, NCT03838042 / 2018-000127-14 / ACTRN12619001768189: INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies

Recruiting
1/2
91
Europe, RoW
Nivolumab and Entinostat, Opdivo
University Hospital Heidelberg, German Cancer Research Center
Solid tumour, Central nervous system (CNS) tumour
06/26
06/27
NCT05500508: Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Terminated
1/2
15
US, RoW
AMXT1501, DFMO, difluoromethyl ornithine monohydrochloride
Aminex Therapeutics, Inc.
Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer, DIPG Brain Tumor, Ovary Cancer, Breast Cancer, Papillary Thyroid Cancer, Head and Neck Cancer, Gastric Cancer, Nsclc, Mesotheliomas Pleural, Mesothelioma Peritoneum, Esophageal Cancer, Diffuse Midline Glioma, H3 K27M-Mutant, Endometrial Cancer, Cervical Cancer, Melanoma, Colorectal Cancer, Glioma, Malignant
12/24
12/24
NCT06208657: Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

Recruiting
1/2
82
Canada, RoW
Paxalisib, Irinotecan, Temozolomide, Pimasertib
Australian & New Zealand Children's Haematology/Oncology Group, Children's Cancer Institute Australia (CCIA), The Hospital for Sick Children, Medical Research Future Fund, Kazia Therapeutics Limited, Day One Biopharmaceuticals, Inc., C17 Council
Childhood Cancer, Childhood Solid Tumor, Childhood Brain Tumor, Recurrent Cancer, Refractory Cancer
12/30
12/35
LIBRETTO-121, NCT03899792 / 2019-000212-28: A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors

Recruiting
1/2
50
Europe, Canada, Japan, US, RoW
LOXO-292, Selpercatinib, LY3527723
Loxo Oncology, Inc., Eli Lilly and Company
Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer, Soft Tissue Sarcoma
12/24
05/29
BLU-285-3101, NCT04773782 / 2020-005234-15: A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling

Active, not recruiting
1/2
37
Europe, Canada, US, RoW
avapritinib, BLU-285
Blueprint Medicines Corporation
Solid Tumor, Unspecified, Child, Relapsed Solid Neoplasm, CNS Tumor
02/25
12/25
NCT05286801: Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

Recruiting
1/2
86
Canada, US, RoW
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Tiragolumab, MTIG7192A, RG6058, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray
National Cancer Institute (NCI)
Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma, Kidney Medullary Carcinoma, Malignant Solid Neoplasm, Poorly Differentiated Chordoma, Recurrent Atypical Teratoid/Rhabdoid Tumor, Recurrent Chordoma, Recurrent Epithelioid Sarcoma, Recurrent Kidney Medullary Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Rhabdoid Tumor, Refractory Atypical Teratoid/Rhabdoid Tumor, Refractory Chordoma, Refractory Epithelioid Sarcoma, Refractory Kidney Medullary Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Rhabdoid Tumor, Rhabdoid Tumor
06/26
06/26
CARE study, NCT04094610 / 2019-003055-11: A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Hourglass Jan 2025 - Jan 2025 : Approval in EU for adv ROS1+ve NSCLC, adv NTRK+ve solid tumors
Checkmark Initial data from P1/2 CARE trial for pediatric and young adult patients with solid tumors at SIOP 2021
Oct 2021 - Oct 2021: Initial data from P1/2 CARE trial for pediatric and young adult patients with solid tumors at SIOP 2021
Recruiting
1/2
75
Europe, Canada, US, RoW
Oral repotrectinib (TPX-0005), Oral repotrectinib (TPX-0005) capsules, Oral repotrectinib (TPX-0005) oral suspension, repotrectinib
Turning Point Therapeutics, Inc., Turning Point Therapeutics, Inc. (a wholly owned subsidiary of Bristol Myers Squibb Company)
Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors
09/26
09/27
NCT04870944: CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Recruiting
1/2
95
US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspirate, BONE MARROW, LIQUID, Human Bone Marrow Aspirate, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Echocardiography, EC, FACT Complex-targeting Curaxin CBL0137, CBL0137
Children's Oncology Group, Incuron LLC, National Cancer Institute (NCI)
Diffuse Midline Glioma, H3 K27M-Mutant, Metastatic Malignant Neoplasm in the Central Nervous System, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma, Recurrent Primary Malignant Central Nervous System Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Osteosarcoma, Refractory Primary Malignant Central Nervous System Neoplasm
12/26
12/26
NCT02879643: Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapsed ALL

Recruiting
1
36
Canada, US, RoW
Marqibo
Therapeutic Advances in Childhood Leukemia Consortium, Spectrum Pharmaceuticals, Inc
ALL, Childhood, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia, Acute
08/21
12/22
NCT04323046: Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults

Recruiting
1
20
Europe, US, RoW
Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
Sabine Mueller, MD, PhD, Pediatric Neuro-Oncology Consortium
Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent Grade III Glioma, Grade III Glioma
03/26
03/29
NCT06333899: Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

Not yet recruiting
1
15
Europe, Canada, US, RoW
Lorlatinib, LOBRENA, Lorlatinib with chemotherapy1, Lorlatinib with chemotherapy 2, Lorlatinib post Radiation
Nationwide Children's Hospital, Pfizer
High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Infant Type Hemispheric Glioma, Glioblastoma, Glioblastoma Multiforme, WHO Grade III Glioma, WHO Grade IV Glioma, Diffuse Midline Glioma, H3K27-altered
09/27
09/34
CONNECT1903, NCT04655404: A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion

Recruiting
1
15
Europe, Canada, US, RoW
Larotrectinib, Larotrectinib surgical
Nationwide Children's Hospital
High Grade Glioma, Diffuse Intrinsic Pontine Glioma
12/25
12/25
NCT06397469: Enhancing Attention and Wellbeing Using Digital Therapeutics

Recruiting
N/A
4000
US
MediTrain, Worder
University of California, San Francisco, National Institute on Aging (NIA)
Aging, MCI, Cognitive Decline
06/29
06/29
MediDream, NCT06633978: Studying the Effects of Digital Interventions on Cognition, Wellbeing, Stress, and Sleep in Older Adults

Recruiting
N/A
90
US
MediTrain, wrist worn multi-sensor watches, Sleep monitor
University of California, San Francisco, National Institute on Aging (NIA)
MCI, Aging
02/26
02/26
NCT06633952: Accelerating Cognitive Gains From Digital Inverventions With Noninvasive Brain Stimulation

Recruiting
N/A
90
US
MediTrain, Worder, noninvasive neurostimulation device, wrist worn multi-sensor watches
University of California, San Francisco, National Institute on Aging (NIA)
Aging, MCI
12/25
12/25
ZERO2, NCT05504772: Precision Medicine for Every Child With Cancer

Recruiting
N/A
3500
RoW
Whole Genome Sequencing, RNA seq, DNA Methylation, Targeted Panel Sequencing, High Throughput Sequencing (in vitro), Patient Derived Xenograft (PDX)(in vivo), Liquid Biopsy
Australian & New Zealand Children's Haematology/Oncology Group, Children's Cancer Institute (CCI), Minderoo Foundation, Medical Research Future Fund
Childhood Cancer, Childhood Solid Tumor, Childhood Brain Tumor, Childhood Leukemia, Refractory Cancer, Relapsed Cancer
07/25
07/30
Strauss, Sandra
SPEARHEAD-1, NCT04044768 / 2019-000589-39: Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Oct 2022 - Jun 2023: BLA submission for treatment of synovial sarcoma
Checkmark Data from cohort 1 of SPEARHEAD-1 trial for synovial sarcoma or myxoid round cell liposarcoma
Nov 2022 - Nov 2022: Data from cohort 1 of SPEARHEAD-1 trial for synovial sarcoma or myxoid round cell liposarcoma
Checkmark Pooled analysis data from trials for sarcoma at AACR 2022
Jun 2022 - Jun 2022: Pooled analysis data from trials for sarcoma at AACR 2022
More
Active, not recruiting
2
52
Europe, Canada, US
afamitresgene autoleucel (previously ADP-A2M4)
Adaptimmune, Adaptimmune LLC
Synovial Sarcoma, Myxoid Liposarcoma
08/21
04/38
ChonDRAgon, NCT04950075: Study of INBRX-109 in Conventional Chondrosarcoma

Recruiting
2
201
Europe, US, RoW
INBRX-109, Placebo
Inhibrx Biosciences, Inc
Conventional Chondrosarcoma
09/25
12/26
CAMPFIRE, NCT05999994: A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

Recruiting
2
105
Europe, Japan, US, RoW
Ramucirumab, LY3009806, Cyclophosphamide, Vinorelbine, Gemcitabine, LY188011, Docetaxel, Abemaciclib, LY2835219, Irinotecan, Temozolomide
Eli Lilly and Company
Neoplasms, Child, Adolescent
05/27
05/27
ImmunoSarc, NCT03277924 / 2016-004040-10: Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas

Completed
1/2
197
Europe
Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent], Sutent, Nivolumab 100 MG/10 ML [Opdivo], Opdivo, Epirubicin, Ifosfamide, Doxorubicin, Dacarbazine, Cisplatin, Methotrexate
Grupo Espanol de Investigacion en Sarcomas
Soft Tissue Sarcoma, Bone Sarcoma
06/24
06/24
NCT03715933: Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Recruiting
1
321
Europe, US
INBRX-109, Carboplatin, Cisplatin, Pemetrexed, 5-fluorouracil, Irinotecan, Temozolomide
Inhibrx Biosciences, Inc
Colorectal Adenocarcinoma, Ewing Sarcoma
06/26
12/26
SCOOP, NCT04544995 / 2020-002359-39: Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors

Recruiting
1
141
Europe, RoW
Niraparib, Dostarlimab
GlaxoSmithKline
Neoplasms
10/29
05/30
NCT03391778 / 2018-004888-31: Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

Recruiting
1
250
Europe, Canada, US, RoW
ADP adoptive cell therapy
Adaptimmune
Neoplasms
04/32
04/32
ICONIC, NCT04132895: Improving Outcomes Through Collaboration in OsteosarComa

Recruiting
N/A
300
Europe
observational only, no interventions are prescribed in protocol.
University College, London, Bone Cancer Research Trust
Osteosarcoma
01/25
01/27
Dileo, Palma
RINGSIDE, NCT04871282 / 2020-005833-34: A Study of AL102 in Patients With Progressing Desmoid Tumors

Active, not recruiting
2/3
192
Europe, US, RoW
AL102, Placebo
Immunome, Inc.
Desmoid, Desmoid Tumor
10/25
10/26
Miller, Rowan
RAMP 301, NCT06072781: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Recruiting
3
270
Europe, Canada, US, RoW
avutometinib, avutometinib (VS-6766), Defactinib, defactinib (VS-6063), Pegylated liposomal doxorubicin, Caelyx, Doxil, Lipodox, Paclitaxel, Nov-Onxol, Onxol, Navaplus, Taxol, Letrozole, Femara, Anastrozole, Arimidex
Verastem, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Australia New Zealand Gynaecological Oncology Group
Low Grade Serous Ovarian Cancer
10/28
02/31
NCT06433219: Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

Recruiting
2
60
Europe, US, RoW
Tuvusertib (M1774), M1774, VXc-400, VRT-1363004, substance code MSC2584415A, Niraparib, GSK3985771, MK-4827, Lartesertib (M4076), M4076, substance code MSC2585823A
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Ovarian Cancer
01/28
01/28
ENGOT-ov60, NCT04625270 / 2020-004264-26: A Study of Avutometinib (VS-6766) V. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer with and Without a KRAS Mutation

Active, not recruiting
2
225
Europe, Canada, US
avutometinib (VS-6766), avutometinib (VS-6766) and defactinib, avutometinib (VS-6766) and VS-6063
Verastem, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer
11/24
12/26
SURPASS-3, NCT05601752 / 2022-003176-16: ADP-A2M4CD8 Monotherapy and in Combination with Nivolumab in HLA-A2+ Subjects with MAGE-A4 Positive Ovarian Cancer

Active, not recruiting
2
66
Europe, Canada, US
Autologous genetically modified ADP-A2M4CD8 cells, Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab
Adaptimmune, GOG Foundation
Ovarian Cancer
08/26
08/26
SL03-OHD-105, NCT05483933: Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancers

Active, not recruiting
1
86
Europe, Canada, US
Pegylated Liposomal Doxorubicin + SL-172154, Doxil, PLD, Caelyx, Mirvetuximab + SL-172154, IMGN853, MIRV
Shattuck Labs, Inc.
Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal Carcinoma
11/24
11/24
NCT06431594: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors

Recruiting
1
240
Europe, Canada, Japan, US, RoW
GSK5733584
GlaxoSmithKline
Solid Tumors, Neoplasms
10/26
06/27
MONITOR-UK, NCT04295577: Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceR

Recruiting
N/A
350
Europe
Niraparib
Royal Marsden NHS Foundation Trust
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
02/24
02/24
BriTROC-2, NCT05537844: Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma

Recruiting
N/A
250
Europe
Liz-Anne Lewsley, Ovarian Cancer Action
Ovarian Cancer, High Grade Serous Carcinoma, Carcinosarcoma, Ovarian, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, BRCA1 Mutation, BRCA2 Mutation
10/24
04/25
McGovern, Ursula
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
NCT04691804 / 2020-006063-28: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting
3
496
Europe, US, RoW
Fuzuloparib , Abiraterone acetate and Prednisone, SHR3162, Fuzuloparib Placebo， Abiraterone acetate and Prednisone
Jiangsu HengRui Medicine Co., Ltd.
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
12/26
12/26
Bertuzzi, Alexia
ISG-ARTICLE, NCT04383119 / 2020-000741-13: Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma

Recruiting
2
100
Europe
Trabectedin, Trabectedin arm, Gemcitabine, Gemcitabine arm, No Intervention: Observational Cohort
Italian Sarcoma Group, PharmaMar
Leiomyosarcoma of Ovary, Soft Tissue Sarcoma
12/25
12/25
TOMAS2, NCT03838744 / 2018-004497-10: Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.

Completed
2
130
Europe
Standard arm: Trabectedin in monotherapy, Trabectedin arm, Experimental arm: Trabectedin + Olaparib, Trabectedin+ Olaparib arm
Italian Sarcoma Group, PharmaMar, AstraZeneca
Advanced Soft Tissue Sarcoma
11/24
11/24
CAMPFIRE, NCT05999994: A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

Recruiting
2
105
Europe, Japan, US, RoW
Ramucirumab, LY3009806, Cyclophosphamide, Vinorelbine, Gemcitabine, LY188011, Docetaxel, Abemaciclib, LY2835219, Irinotecan, Temozolomide
Eli Lilly and Company
Neoplasms, Child, Adolescent
05/27
05/27
Breast-Sarc, NCT04749446: Study on Clinical Features and Outcomes of Breast Sarcoma

Recruiting
N/A
300
Europe
Treatment of Breast Sarcoma according clinical practice (includes drugs, surgery or any other received treatments)
Italian Sarcoma Group
Breast Sarcoma
12/25
12/25
EHE, NCT06408441: The Epithelioid Hemangioendothelioma Registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN)

Recruiting
N/A
100
Europe
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, EHE Rare Cancer Charity UK
Epithelioid Hemangioendothelioma, Sarcoma,Soft Tissue
12/33
12/33
NCT04282083: Protocol ITANET - Registry

Recruiting
N/A
3600
Europe
Italian Association Neuroendocrine Tumors
Gastro-entero Pancreatic Neuroendocrine Tumors
07/27
07/32
EWOss, NCT04845893: Observational Study on Skeletal Ewing's Sarcoma

Recruiting
N/A
100
Europe
Treatment of Ewings Sarcoma of bone according clinical practice (includes drugs, surgery, radiotherapy or any other received treatments)
Italian Sarcoma Group
Ewing Sarcoma of Bone
05/28
05/28
Fisher, Corinne
JUVE-X, NCT03773965 / 2017-004471-31: A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

Recruiting
3
190
Europe, Japan, RoW
Baricitinib, LY3009104
Eli Lilly and Company
Juvenile Idiopathic Arthritis
07/31
07/31
Gietka, Piotr
VECTORS, NCT06257706: - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease

Recruiting
4
304
Europe, Canada, US, RoW
Vedolizumab
Alimentiv Inc., Takeda
Moderately to Severely Active Crohn's Disease, Crohn Disease, Disease Crohn
01/27
09/28
NCT04088396 / 2017-004495-60: A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)

Recruiting
3
58
Europe, Japan, RoW
Baricitinib, LY3009104, Tocilizumab
Eli Lilly and Company
Systemic Juvenile Idiopathic Arthritis
04/26
05/26
JUVE-X, NCT03773965 / 2017-004471-31: A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

Recruiting
3
190
Europe, Japan, RoW
Baricitinib, LY3009104
Eli Lilly and Company
Juvenile Idiopathic Arthritis
07/31
07/31
Eijkelenburg, Natasha van
CAMPFIRE, NCT05999994: A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

Recruiting
2
105
Europe, Japan, US, RoW
Ramucirumab, LY3009806, Cyclophosphamide, Vinorelbine, Gemcitabine, LY188011, Docetaxel, Abemaciclib, LY2835219, Irinotecan, Temozolomide
Eli Lilly and Company
Neoplasms, Child, Adolescent
05/27
05/27
NCT04610736 / 2020-003733-38: TEMOkids Study : A Phase I Pediatric Study for KIMOZO, Oral Suspension of Temozolomide

Active, not recruiting
1
49
Europe
Temozolomide Oral Suspension, KIMOZO, Ped-TMZ
Orphelia Pharma, ClinSearch
Pediatric Cancer
01/23
07/23
Sivabalasingham, Suganya
LIBRETTO-531, NCT04211337 / 2019-001978-28: A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

Active, not recruiting
3
291
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Cabozantinib, Vandetanib
Loxo Oncology, Inc., Eli Lilly and Company
Medullary Thyroid Cancer
05/23
02/26
Almeida, Beverley
NCT04088396 / 2017-004495-60: A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)

Recruiting
3
58
Europe, Japan, RoW
Baricitinib, LY3009104, Tocilizumab
Eli Lilly and Company
Systemic Juvenile Idiopathic Arthritis
04/26
05/26
JUVE-X, NCT03773965 / 2017-004471-31: A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

Recruiting
3
190
Europe, Japan, RoW
Baricitinib, LY3009104
Eli Lilly and Company
Juvenile Idiopathic Arthritis
07/31
07/31
Stoneham, Sara
AGCT1531, NCT03067181 / 2018-004141-17: Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

Recruiting
3
2097
Europe, Canada, Japan, US, RoW
Best Practice, standard of care, standard therapy, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bleomycin Sulfate, Blanoxan, BleMomycine, Blenoxane, Bleo-cell, Bleo-S, Bleocin, Bleolem, Bleomycin Sulfas, Bleomycin Sulphate, Bleomycini Sulfas, Blexane, Oil Bleo, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP16, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Pharmacogenomic Study, PHARMACOGENOMIC, Pulmonary Function Test, lung function test, PFT, Pulmonary Function Testing, Pulmonary Function Tests, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
Children's Oncology Group, National Cancer Institute (NCI)
Childhood Extracranial Germ Cell Tumor, Extragonadal Embryonal Carcinoma, Germ Cell Tumor, Malignant Germ Cell Tumor, Malignant Ovarian Teratoma, Stage I Ovarian Choriocarcinoma, Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage I Ovarian Teratoma AJCC v6 and v7, Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7, Stage I Testicular Choriocarcinoma AJCC v6 and v7, Stage I Testicular Embryonal Carcinoma AJCC v6 and v7, Stage I Testicular Seminoma AJCC v6 and v7, Stage I Testicular Yolk Sac Tumor AJCC v6 and v7, Stage II Ovarian Choriocarcinoma, Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7, Stage II Testicular Choriocarcinoma AJCC v6 and v7, Stage II Testicular Embryonal Carcinoma AJCC v6 and v7, Stage II Testicular Yolk Sac Tumor AJCC v6 and v7, Stage III Ovarian Choriocarcinoma, Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7, Stage III Testicular Choriocarcinoma AJCC v6 and v7, Stage III Testicular Embryonal Carcinoma AJCC v6 and v7, Stage III Testicular Yolk Sac Tumor AJCC v6 and v7, Stage IV Ovarian Choriocarcinoma, Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7, Testicular Mixed Choriocarcinoma and Embryonal Carcinoma, Testicular Mixed Choriocarcinoma and Teratoma, Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
06/27
06/27
LIBRETTO-121, NCT03899792 / 2019-000212-28: A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors

Recruiting
1/2
50
Europe, Canada, Japan, US, RoW
LOXO-292, Selpercatinib, LY3527723
Loxo Oncology, Inc., Eli Lilly and Company
Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer, Soft Tissue Sarcoma
12/24
05/29

Download Options